Fate Therapeutics Inc. Insider Trading

FATE

Last 12 months

Insiders sold 336K and bought nothing on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. The last open-market buy by an executive or director was in Dec 2024.

Net open-market

−336K

0 buys · 7 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 3

executives and directors

Last open-market buy

Dec 2024

Dec 20, 2024

Get an email when FATE's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Nov 3	Kamal Adawi Chief Financial Officer	SoldNo plan	6,582	$2.05	14K	6.6%	Form 4
Aug 4	Cindy Tahl See Remarks	SoldNo plan	38,800	$2.46	95K	6.2%	Form 4
Aug 4	Bahram Valamehr President and CEO	SoldNo plan	43,947	$2.46	108K	6.9%	Form 4
May 20	Cindy Tahl See Remarks	SoldNo plan	25,590	$1.88	48K	3.9%	Form 4
May 20	Bahram Valamehr President and CEO	SoldNo plan	28,946	$1.88	54K	4.4%	Form 4
Jan 9	Cindy Tahl See Remarks	SoldNo plan	10,589	$1.06	11K	2.7%	Form 4
Jan 9	Bahram Valamehr President and CEO	SoldNo plan	5,190	$1.07	6K	1.5%	Form 4
Aug 4, 2025	Cindy Tahl See Remarks	SoldNo plan	9,037	$1.06	10K	2.2%	Form 4
Aug 4, 2025	Bahram Valamehr President and CEO	SoldNo plan	14,466	$1.06	15K	4.1%	Form 4
Jan 10, 2025	Jerome Charles Bressi See Remarks	SoldNo plan	5,980	$1.55	9K	2.2%	Form 4
Jan 10, 2025	Cindy Tahl See Remarks	SoldNo plan	5,654	$1.55	9K	1.7%	Form 4
Jan 10, 2025	Bahram Valamehr President and CEO	SoldNo plan	8,705	$1.54	13K	2.4%	Form 4
Dec 20, 2024	Jeremy Green Director	Bought	397,964	$1.68	669K	3.2%	Form 4
Dec 20, 2024	Jeremy Green Director	SoldNo plan	341,633	$1.68	574K	2.6%	Form 4

Nov 3No plan
Kamal Adawi
Chief Financial Officer · sold 6,582 at $2.05
14K
6.6% of stake
Aug 4No plan
Cindy Tahl
See Remarks · sold 38,800 at $2.46
95K
6.2% of stake
Aug 4No plan
Bahram Valamehr
President and CEO · sold 43,947 at $2.46
108K
6.9% of stake
May 20No plan
Cindy Tahl
See Remarks · sold 25,590 at $1.88
48K
3.9% of stake
May 20No plan
Bahram Valamehr
President and CEO · sold 28,946 at $1.88
54K
4.4% of stake
Jan 9No plan
Cindy Tahl
See Remarks · sold 10,589 at $1.06
11K
2.7% of stake
Jan 9No plan
Bahram Valamehr
President and CEO · sold 5,190 at $1.07
6K
1.5% of stake
Aug 4, 2025No plan
Cindy Tahl
See Remarks · sold 9,037 at $1.06
10K
2.2% of stake
Aug 4, 2025No plan
Bahram Valamehr
President and CEO · sold 14,466 at $1.06
15K
4.1% of stake
Jan 10, 2025No plan
Jerome Charles Bressi
See Remarks · sold 5,980 at $1.55
9K
2.2% of stake
Jan 10, 2025No plan
Cindy Tahl
See Remarks · sold 5,654 at $1.55
9K
1.7% of stake
Jan 10, 2025No plan
Bahram Valamehr
President and CEO · sold 8,705 at $1.54
13K
2.4% of stake
Dec 20, 2024
Jeremy Green
Director · bought 397,964 at $1.68
669K
3.2% of stake
Dec 20, 2024No plan
Jeremy Green
Director · sold 341,633 at $1.68
574K
2.6% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch FATE, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with FATE

CompareIntrinsic value

ATRAAtara Biotherapeutics, Inc.

$8.37+2.07%15

ZEOXZeo Scientifix Inc.

$0.97+0.00%25

CRISCuris Inc.

$1.11+56.34%25

TCRXTScan Therapeutics Inc.

$0.21+11.11%10

SRZNSurrozen, Inc.

$31.65+5.08%10

TSHATaysha Gene Therapies Inc.

$4.36+6.60%40

CGONCG Oncology, Inc.

$67.71+5.70%40

DBVTDBV Technologies S.A.

$9.94-1.68%10

Held by ETFs

FATE is in 3 US ETFs. The largest of them, with FATE's weight in each:

Spot a number that looks wrong? Check it in FATE's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing FATE

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.